Licensing Clinical-Stage Assets to Greater China

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
The rise of Chinese bio and pharma companies has provided many US and European companies with the opportunity to raise non-dilutive capital by licensing rights to clinical stage assets in the Greater China Territory. What strategies and tactics should be considered, what peculiarities exist within this Territory, what is the process like and what key deal terms will be negotiated?
Speakers
photo
Chief Business Officer
Everest Medicines
photo
Co-Chair, Life Sciences Practice
Mintz
photo
Vice President, Head of Corporate Development
Blueprint Medicines
photo
VP, Business Development
Spero Therapeutics